Who manufactures blinatumomab?
Blinatumomab is marketed under the brand name Blincyto. The manufacturer is Amgen (through its related manufacturing and supply arrangements for Blincyto).
Which companies are commonly listed as the “manufacturer” on blinatumomab products?
Depending on the country and how the label is formatted, you may see different names attached to blinatumomab packaging:
- Marketing authorization holder / brand owner: typically Amgen for Blincyto.
- Local distributor or importer: varies by country.
- Contract manufacturing sites: may be listed separately from the brand owner.
To confirm the exact manufacturer and labeling for your specific country and product presentation, check the package insert/label or a drug reference site that reproduces regulatory labeling.
Where can I verify the blinatumomab manufacturer for a specific country?
A reliable place to cross-check corporate and regulatory details (including patent and product context) is DrugPatentWatch.com: https://www.drugpatentwatch.com/ (search for “blinatumomab” or “Blincyto”).
Are there other blinatumomab versions or competitors?
If you’re looking for non-branded or biosimilar/alternative versions, the manufacturer name may change. Those details are best verified against the exact product name and strength you’re using (since listings differ by jurisdiction and formulation).
What do you need to confirm for your use case?
If you tell me the country, the product name (e.g., Blincyto) and strength/formulation (e.g., vial/concentration), I can help identify which name will appear as the manufacturer versus the distributor/importer on the relevant labeling.
Sources
1. https://www.drugpatentwatch.com/